HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Malcolm Boyce Selected Research

YF 476

1/2020Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
1/2017Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
12/2016Potential clinical indications for a CCK2 receptor antagonist.
1/2016Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1.
5/2015Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
5/2015Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.
12/2013The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.
1/2013Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
1/2013The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Malcolm Boyce Research Topics

Disease

4Asthma (Bronchial Asthma)
09/2018 - 10/2005
3Neuroendocrine Tumors (Neuroendocrine Tumor)
01/2020 - 05/2015
3Atrophic Gastritis
01/2017 - 01/2013
2Infections
01/2019 - 12/2013
2Human Influenza (Influenza)
01/2019 - 01/2018
2Dyspepsia (Indigestion)
02/2017 - 05/2015
2Hyperplasia
02/2017 - 05/2015
2Achlorhydria (Hypochlorhydria)
01/2017 - 01/2013
2Inflammation (Inflammations)
12/2013 - 10/2005
2Dizziness (Lightheadedness)
04/2008 - 11/2004
1Hot Flashes
12/2020
1Rheumatoid Arthritis
11/2020
1Injection Site Reaction
01/2017
1Alcoholism (Alcohol Abuse)
01/2017
1Pancreatic Neoplasms (Pancreatic Cancer)
12/2016
1Multiple Sclerosis
02/2016
1Neoplasms (Cancer)
01/2016
1Adenocarcinoma
01/2016
1Rare Diseases (Rare Disease)
05/2015
1Carcinoid Tumor (Carcinoid)
05/2015
1Gastritis
12/2013
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
08/2013
1Tetanus
08/2013
1Stomach Ulcer (Gastric Ulcer)
01/2013
1Chronic Obstructive Pulmonary Disease (COPD)
06/2012
1Respiratory Insufficiency (Respiratory Failure)
08/2011
1Migraine Disorders (Migraine)
01/2009
1Hiccup (Hiccups)
04/2008
1Abdominal Pain (Pain, Abdominal)
04/2008
1Vomiting
04/2008
1Obesity
04/2008
1Nausea
04/2008
1Headache (Headaches)
04/2008
1Orthostatic Hypotension (Postural Hypotension)
11/2004

Drug/Important Bio-Agent (IBA)

9YF 476IBA
01/2020 - 01/2013
8GastrinsIBA
02/2017 - 01/2013
4Cholecystokinin B ReceptorIBA
01/2017 - 01/2013
2EndonucleasesIBA
01/2019 - 01/2018
2sfericaseIBA
01/2019 - 01/2018
2Esomeprazole (Nexium)FDA Link
02/2017 - 01/2013
2Chromogranin AIBA
01/2017 - 05/2015
2Hormones (Hormone)IBA
01/2016 - 01/2013
2Pharmaceutical PreparationsIBA
05/2015 - 04/2008
2AllergensIBA
06/2012 - 10/2005
1Gonadotropin-Releasing Hormone (GnRH)FDA Link
12/2020
1Adalimumab (Humira)FDA Link
11/2020
1Biosimilar PharmaceuticalsIBA
11/2020
1FKB327IBA
11/2020
1Antiviral Agents (Antivirals)IBA
01/2019
1Monoclonal AntibodiesIBA
09/2018
1AntigensIBA
09/2018
1Interleukin-13IBA
09/2018
1Immunoglobulin FragmentsIBA
09/2018
1PowdersIBA
09/2018
1Nitric Oxide (Nitrogen Monoxide)FDA Link
09/2018
1ProdrugsIBA
01/2018
1Proton Pump InhibitorsIBA
02/2017
1revusiranIBA
01/2017
1nalmefene (Revex)FDA Link
01/2017
1Opioid Receptors (Opioid Receptor)IBA
01/2017
1Narcotic Antagonists (Opioid Antagonists)IBA
01/2017
1Z-360IBA
12/2016
1Interferon beta-1aFDA Link
02/2016
1MicroRNAs (MicroRNA)IBA
01/2016
1Pentagastrin (Peptavlon)FDA Link
05/2015
1Rabeprazole (Aciphex)FDA Link
05/2015
1Immunoglobulin G (IgG)IBA
08/2013
1AntibodiesIBA
08/2013
1keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA
08/2013
1Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
01/2013
13- (3- tert- butylsulfanyl- 1- (4- (6- ethoxypyridin- 3- yl)benzyl)- 5- (5- methylpyridin- 2- ylmethoxy)- 1H- indol- 2- yl)- 2,2- dimethylpropionic acidIBA
01/2013
1Diclofenac (SR 38)FDA LinkGeneric
01/2013
1Biomarkers (Surrogate Marker)IBA
01/2013
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
01/2013
1GhrelinIBA
01/2013
1fluticasone furoateFDA Link
06/2012
1vilanterolIBA
06/2012
1Adrenal Cortex Hormones (Corticosteroids)IBA
06/2012
1Opioid Analgesics (Opioids)IBA
08/2011
1frovatriptan (Allegro)FDA Link
01/2009
1CannabinoidsIBA
04/2008
1N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamideIBA
04/2008
1Integrin alpha4beta1 (VLA-4)IBA
10/2005
13- (N- (3,4- dimethoxybenzyl)- 2- (2- (3- methoxy- 4- (3- o- tolylureido)phenyl)acetylamino)acetamido)propanoic acidIBA
10/2005
1Thioridazine (Mellaril)FDA LinkGeneric
11/2004
1Donepezil (Aricept)FDA LinkGeneric
11/2004

Therapy/Procedure

2Therapeutics
02/2017 - 06/2012
1Aftercare (After-Treatment)
05/2015